ReviewCurrent pharmaceutical design2014
Endocannabinoid signaling in the etiology and treatment of major depressive illness.
Review in Current pharmaceutical design, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review.BMC psychiatry · 2024Pooled it
- Trial
- Biochemical Mechanisms of Cellular Stress Adaptation in the Pathogenesis of Chronic Diseases.Molecules (Basel, Switzerland) · 2026Review
- Unpredictable Chronic Mild Stress Upregulates Dopamine Receptor Expression Independent of Fatty Acid-Binding Protein 7 Gene Deletion.Neurochemical research · 2026Article
- Pharmacogenetic association study of cannabis use in chronic pain.Journal of cannabis research · 2026Article
- PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.Neuroscience bulletin · 2026Review
- Associations between cannabis use frequency and suicidal thoughts and behaviors: A clinical longitudinal sibling study.Addictive behaviors reports · 2025Article
- Gastrodin Ameliorates Post-Stroke Depressive-Like Behaviors Through Cannabinoid-1 Receptor-Dependent PKA/RhoA Signaling Pathway.Molecular neurobiology · 2025Article
- Cannabinoid type 2 receptor inhibition enhances the antidepressant and proneurogenic effects of physical exercise after chronic stress.Translational psychiatry · 2024Article
- Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.International journal of molecular sciences · 2023Article
- Alcohol-Endocannabinoid Interactions: Implications for Addiction-Related Behavioral Processes.Alcohol research : current reviews · 2022Review
- Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain.Pharmacological reports : PR · 2021Article
- Integrating Endocannabinoid Signalling In Depression.Journal of molecular neuroscience : MN · 2021Review
- Circulating endocannabinoids and prospective risk for depression in trauma-injury survivors.Neurobiology of stress · 2021Article
- Down and High: Reflections Regarding Depression and Cannabis.Frontiers in psychiatry · 2021Review
- From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?Frontiers in psychiatry · 2021Review
- Meet Your Stress Management Professionals: The Endocannabinoids.Trends in molecular medicine · 2020Review
- Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease.World journal of gastroenterology · 2020Review
- Dual pharmacological inhibitor of endocannabinoid degrading enzymes reduces depressive-like behavior in female rats.Journal of psychiatric research · 2020Article
- An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective.Current neuropharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this review is to examine human and preclinical data that are relevant to the following hypotheses. The first hypothesis is that deficient CB1R-mediated signaling results in symptoms that mimic those seen in depression. The second hypothesis is that activation of CB1R-mediated signaling results in behavioral, endocrine and other effects that are similar to those produced by currently used antidepressants. The third hypothesis is that conventional antidepressant therapies act through enhanced CB1R mediated signaling. Together the available data indicate that activators of CB1R signaling, particularly inhibitors of fatty acid amide hydrolase, should be considered for clinical trials for the treatment of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.